{"url_path":"/sec/ormp/8-k/2026-06-30/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 ** **Other","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1176309/0001213900-26-073709-index.html","accession_number":"0001213900-26-073709","cik":"0001176309","ticker":"ORMP","issuer_name":"ORAMED PHARMACEUTICALS INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1176309/0001213900-26-073709-index.html","primary_entity_key":"0001176309","primary_entity_name":"ORAMED PHARMACEUTICALS INC."},"word_count":425,"has_tables":true,"body_markdown":"**Item 8.01.** **Other\nEvents.**\n\n** **\n\nOn June 25, 2026, the Company and Scilex Holding Company (“Scilex”) agreed to a further extension (the “Extension Agreement”)\nof the outstanding payment obligations, including the outstanding principal amount, any accrued interest thereon and any other fees (the\n“Note Obligations”), owed by Scilex to the Company pursuant to (i) the Senior Secured Promissory Note dated September 21,\n2023, as amended (the “Tranche A Note”) with outstanding Note Obligations equal to an aggregate of approximately $29.5 million\nas of June 30, 2026, (ii) the Senior Secured Convertible Note dated October 8, 2024, as amended (the “Tranche B Note” and,\ntogether with the Tranche A Note, the “Notes”), with outstanding Note Obligations equal to an aggregate of approximately $6.7\nmillion (representing the amortization payments due April 1, 2026 and July 1, 2026), and (iii) the prior agreement to extend the maturity\ndate of the Notes to June 15, 2026, in consideration of Scilex agreeing to pay to the Company $1 million in cash (the “Extension\nObligation” and, collectively with the Note Obligations, the “Obligations”).\n\n \n\nPursuant to the Extension Agreement, Scilex agreed to pay the Obligations to the Company in cash as follows: (i) $0.5 million, which the\nCompany received on June 25, 2026; (ii) $5 million on or before July 31, 2026; and (iii) the entire remaining balance of the Obligations\non or before September 30, 2026. Amounts received are to be applied first to the Extension Obligation (until the first $1 million has\nbeen so applied), thereafter to the Tranche B Note (covering the amortization payments due April 1, 2026 and July 1, 2026), and thereafter\nto the Tranche A Note.\n\n \n\nIf Scilex fails to satisfy the Obligations in full by September 30, 2026 (such date, the “Due Date”), then, notwithstanding\nthe foregoing order of application, the first $1.5 million received by the Company shall not be credited against the Obligations and will\nbe deemed, retroactively and for all purposes, an extension fee fully earned by and retained by the Company, and the Obligations will\nremain outstanding in full as if such amount had not been applied. In addition, if Scilex fails to satisfy the Obligations by the Due\nDate, Scilex has agreed to satisfy the remaining Obligations through the delivery of shares of common stock, par value $0.0001 per share,\nof Scilex (or of an affiliate of Scilex) which such shares will covered by an effective registration statement and will be issued free\nof restrictive legends and transfer restrictions, on such terms to be mutually agreed to by Oramed and Scilex."}